Drugs / Polyclonal Regulatory T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02711826 | Sep 2016 → Aug 2023 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyclonal Regulatory T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02711826 ↗ |
| Modality | Cell therapy | “A person's Tregs can be grown in the laboratory to increase their number (polyTreg). These Tregs can be given back through a needle placed in a vein (IV).” NCT02711826 ↗ |
| Route | Intravenous | “given back through a needle placed in a vein (IV)” NCT02711826 ↗ |